Tom Dugan is a proven, hands-on senior executive who has transformed businesses, established new market opportunities, and driven growth in the face of strong competition. He co-founded 360 Life Sciences Advisors working with private equity and venture capital firms to assess new investment opportunities and improve performance at portfolio companies. Most recently, Tom was the President of Integrum, Inc., the pioneer in osseointegrated orthopedic implants that improve the lives of those with limb loss. Previously, he held multiple leadership positions including Chief Executive Officer at Amniox Medical, a pioneer in amniotic membrane products for wound care and surgical applications, President at SurgiQuest, Inc., President of the Americas for Smith and Nephew Wound Management, and served in senior roles at SonoSite, Rita Medical Systems and Tyco Healthcare. Tom served on the board of directors of Rita Medical Systems (NASDAQ: RITA), which was acquired byAngioDynamics, and various venture-backed medical device companies. He chaired the Wound Healing and Tissue Regeneration sector of AdvaMed and served on the board of MITA, the industry trade group for medical imaging.
Jason Matuszewski brings a wealth of experience in strategic operations planning and technical projects management from his rigorous technical background. His diverse expertise includes continuous process improvement, training and development programs, regulatory compliance and best practices implementation, and advanced problem solving. He began his career as a technical engineer working for Adecco at SC Johnson in 2009, where he developed comprehensive maintenance plans to support manufacturing processes at scale. He then transitioned to manufacturing and quality engineering for major organizations, including ATI Ladish Forging, Nemak, and HUSCO International, where he spearheaded process design and implementation, solved complex supply-chain and manufacturing problems, and improved product sourcing and purchasing. His philanthropic work with the Juvenile Diabetes Research Foundation sparked an interest in biotech, leading him to co-found Biostem Technologies in 2014. As CEO he has leveraged his expertise to optimize tissue sourcing, strategically build out a 6,000 square foot tissue processing facility that is fully compliant with FDA 210, 211, 1271, and AATB standards, and put together an expert team of professionals to support the company’s continued growth. Jason holds a B.S. in Mechanical Engineering Technology and a minor in Mathematics from the Milwaukee School of Engineering and is Six Sigma Black Belt certified. He also serves as a Processing and Distribution Council Member for the American Association of Tissue Banks (AATB), as well as serves as a member of the Government Affairs committee for BioFlorida.
Mr. Poe is a veteran executive with more than 25 years of financial experience across various industries, including life sciences, medical devices and healthcare services. He currently serves as Chief Financial Officer (CFO) of Midi Health, a leader in women's healthcare. Previously, he served as CFO of Jumpcode Genomics, a genomic tools company unlocking the power of next-generation sequencing using CRISPRclean technology and CFO at Genome Medical, a genomic telehealth provider, where he led all aspects of finance at both companies. Mr. Poe has also held the positions of Vice President of Finance at Illumina, the leader in genomics technology; CFO at Sotera Wireless, a medical device start-up; and Vice President of Finance at Inverness Medical Innovations, a point-of-care diagnostics company acquired by Abbott. Mr. Poe received his bachelor's degree from Bucknell University and his MBA from the University of Chicago Booth School of Business
Andrew Van Vurst is a veteran and manufacturing operations expert with over eight years of experience working in FDA-regulated pharmaceutical and tissue processing firms. Before beginning his biopharmaceutical career, Andrew served as an aviation mechanic and flight captain in the United States Marine Corps. His military background instilled a high level of discipline, a strong commitment to compliance with industry protocol, and a paradigm for effective leadership that has served him well in subsequent roles. He co-founded Biostem Technologies in 2014 and played a pivotal role in the development of the company, working to establish revenue streams, ensure compliance with FDA and state pharmacy board guidelines, and adhere to FINRA and SEC guidelines for eventual public listing. During the early years with BioStem Technologies, he worked as Director of Operations for Nesvik Pharmaceuticals and Qualified Pharma Ingredients, where he managed research and development activities for four 505(b)(2) products and built out an API repackaging facility from the ground up until 2019. Throughout these roles, he brought several compounds from the idea phase to pre-IND submission and eventually sold the API repackaging business. Today, he continues to oversee lab production and quality assurance operations, supporting Biostem’s excellence in tissue processing. Andrew studied at Florida Gulf Coast University and has completed Landmark Courses to hone advanced leadership skills. He serves as a Processing and Distribution Council Member for the American Association of Tissue Banks (AATB) and is an AATB-certified Tissue Banking Specialist.
Kenneth Warrington, Ph.D., has decades of broad expertise across the cell and gene therapy product development continuum from discovery through GMP-compliant manufacturing to support IND-enabling pre-clinical and early-stage clinical programs. He has deep knowledge in advanced therapy manufacturing, including live attenuated and virus-like particle vaccines, live challenge viruses, viral vectors, and cell & gene-modified cell therapies. He served on the faculty at the University of Florida, Pediatrics-Division of Cellular & Molecular Therapy, with a research program focused on AAV vector development and production. Following his transition into industry in 2008, Dr. Warrington has held the lead technical operation and business development roles for global contract testing and manufacturing organizations, including Meridian Life Science, SGS Life Science, and Wuxi Apptec. He was formerly the SVP of Operations and Business Development at Biostem Life Sciences before assuming the role of chairman of the scientific advisory board. Dr. Warrington is currently Head of Strategy & Innovation and a Sr. Director of Business Development at GenScript ProBio, leading their gene & cell therapy CMC services, and Chief Technology Officer at Lacerta Therapeutics. He holds a B.S. in Biology & Chemistry from St. Lawrence University and a Ph.D. in Pharmacology & Experimental Therapeutics from the University of Florida.
Mr. Daly is an award-winning executive leader with over thirty-five years of experience and a strong track record of success in operations, strategy, sales, marketing, fundraising, and partnership-building. Mr. Daly serves as the Global VP MedTech Data Delivery and previously served as Global VP Commercial Solutions at IQVIA Holdings, where he was responsible for leading a global strategic MedTech Commercial Solutions business unit. Prior to that, he held the position of President and CEO at Cohera Medical, an early-stage commercial-stage life sciences company developing biomaterials for surgical adhesives, sealants, and drug delivery products that was acquired by global investment firm, KKR. At Cohera, Mr. Daly spearheaded the development of a novel delivery device for synthetic surgical adhesive that maintained a two-year shelf life and received the Businesswire 2012 Medical Design Excellence Award. Mr. Daly also held leadership positions for more than a decade at Johnson & Johnson.